Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre

Manno, G.; Cruciani, Mario; Romanò, Luca; Scapolan, Sara; Mentasti, M.; Lorini, Renata; Minicucci, L.

doi:10.1016/j.ijantimicag.2004.11.009

Cited by 34 publications

(37 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with our findings in a study that aims to determine antibiotic resistance of CF in P. aeruginosa isolates, ceftazidime resistance was detected as 14 % while there is no resistance for colistin (21 Both studies also found high resistance for amikacin. In a multicentre study in Australia, they also found that resistance for aminoglycoside as 43% in the pediatric patient group and 53% in adult patient group (22).…”

Section: Discussionsupporting

confidence: 91%

Comparison of virulence factors and antibiotic resistance of Pseudomonas aeruginosa strains isolated from patients with and without cystic fibrosis

Maçin

Akarca

Şener

et al. 2017

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

Its rising incidence, virulence factors and antibiotic resistance rate makes it difficult to treat Pseudomonas aeruginosa infections. The aim of this study was to compare virulence factors and antibiotic resistance of P. aeruginosa isolates from cystic fibrosis (CF) and other lower respiratory tract infections. Isolates from patients (n=125) were divided into two groups. The isolates in the first group were from CF patients (n=64). And in the other group isolates were from lower respiratory tract samples, from patients that did not have CF (n=61

show abstract

Section: Discussionsupporting

confidence: 91%

Comparison of virulence factors and antibiotic resistance of Pseudomonas aeruginosa strains isolated from patients with and without cystic fibrosis

Maçin

Akarca

Şener

et al. 2017

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

show abstract

“…tobramycin or amikacin used to treat prechronic infections of P. aeruginosa in CF patients as well as acute exacerbations that occur following the onset of chronicity (10,64,82). Aminoglycoside use in treating pulmonary infections in CF patients is, however, associated with resistance development (9,30,58,61), which complicates antipseudomonal chemotherapy.…”

mentioning

confidence: 99%

Determinants of Intrinsic Aminoglycoside Resistance in Pseudomonas aeruginosa

Krahn

Gilmour

Tilak

et al. 2012

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Screening of a transposon insertion mutant library of Pseudomonas aeruginosa for increased susceptibility to paromomycin identified a number of genes whose disruption enhanced susceptibility of this organism to multiple aminoglycosides, including tobramycin, amikacin, and gentamicin. These included genes associated with lipid biosynthesis or metabolism (lptA, faoA), phosphate uptake (pstB), and two-component regulators (amgRS, PA2797-PA2798) and a gene of unknown function (PA0392). Deletion mutants lacking these showed enhanced panaminoglycoside susceptibility that was reversed by the cloned genes, confirming their contribution to intrinsic panaminoglycoside resistance. None of these mutants showed increased aminoglycoside permeation of the cell envelope, indicating that increased susceptibility was not related to enhanced aminoglycoside uptake owing to a reduced envelope barrier function. Several mutants (pstB, faoA, PA0392, amgR) did, however, show increased cytoplasmic membrane depolarization relative to wild type following gentamicin exposure, consistent with the membranes of these mutants being more prone to perturbation, likely by gentamicin-generated mistranslated polypeptides. Mutants lacking any two of these resistance genes in various combinations invariably showed increased aminoglycoside susceptibility relative to single-deletion mutants, confirming their independent contribution to resistance and highlighting the complexity of the intrinsic aminoglycoside resistome in P. aeruginosa. Deletion of these genes also compromised the high-level panaminoglycoside resistance of clinical isolates, emphasizing their important contribution to acquired resistance.

show abstract

“…About 4 of 5 adults with CF (age: 26 to 30 years) are infected by Pseudomonas aeruginosa (24). Ceftazidime is still one of the most active antibiotics against P. aeruginosa isolates from CF patients and has activity against species belonging to the Burkholderia cepacia complex (45,46,64). Infections by B. cepacia are of particular interest to CF patients, since B. cepacia can cause a rapid deterioration of lung function (29,71).…”

mentioning

confidence: 99%

Population Pharmacokinetic Comparison and Pharmacodynamic Breakpoints of Ceftazidime in Cystic Fibrosis Patients and Healthy Volunteers

Bulitta

Landersdorfer

Hüttner

et al. 2010

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Despite the promising activity of ceftazidime against Pseudomonas aeruginosa and Burkholderia cepacia, there has not yet been a study that directly compared the pharmacokinetics (PK) of ceftazidime in cystic fibrosis (CF) patients and healthy volunteers by population PK methodology. We assessed the population PK and PK/pharmacodynamic (PD) breakpoints of ceftazidime in CF patients and healthy volunteers.

show abstract

Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre

Cited by 34 publications

References 30 publications

Comparison of virulence factors and antibiotic resistance of Pseudomonas aeruginosa strains isolated from patients with and without cystic fibrosis

Comparison of virulence factors and antibiotic resistance of Pseudomonas aeruginosa strains isolated from patients with and without cystic fibrosis

Determinants of Intrinsic Aminoglycoside Resistance in Pseudomonas aeruginosa

Population Pharmacokinetic Comparison and Pharmacodynamic Breakpoints of Ceftazidime in Cystic Fibrosis Patients and Healthy Volunteers

Contact Info

Product

Resources

About